Tetragenetics, Inc. is an early-stage biotechnology company meeting the needs of customers who seek a cost-effective alternative platform technology for the production of genetically engineered proteins. We accomplish this by harnessing the unique biology of Tetrahymena thermophila. Our technology is particularly well suited to the production of eucaryotic membrane and secretory proteins that are difficult to express in conventional systems. Such proteins include vaccine antigens, monoclonal antibodies, and a variety of therapeutic proteins for the treatment and prevention of human and animal disease. Development of recombinant subunit vaccines against human pathogens is now underway, and long-range efforts are being directed towards large-scale expression of genetically engineered monoclonal antibodies. Additionally, we are actively pursuing both an internal pipeline of hard-to-make proteins and monoclonal antibodies, as well as proteins in partnership with a number of biopharmaceutical companies.